By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Markets > Stocks > Martin Shkreli-founded drug company files for bankruptcy
Stocks

Martin Shkreli-founded drug company files for bankruptcy

News Room
Last updated: 2023/05/11 at 10:53 PM
By News Room
Share
3 Min Read
SHARE

© Reuters. FILE PHOTO: Former drug company executive Martin Shkreli exits U.S. District Court after being convicted of securities fraud, in the Brooklyn borough of New York City, U.S., August 4, 2017. REUTERS/Carlo Allegri

By Dietrich Knauth

NEW YORK (Reuters) – Vyera Pharmaceuticals, which previously settled price-fixing charges that resulted in founder Martin Shkreli being banned from the pharmaceutical industry, filed for bankruptcy late Tuesday to sell its assets.

Vyera said its bankruptcy was the result of declining profits, increased competition for generic drugs, and litigation alleging that Vyera suppressed competition for its most valuable drug, Daraprim.

Daraprim is a life-saving anti-parasitic medicine that Shkreli infamously raised the price on by more than 4000% and worked to choke off generic competition for after the company acquired the drug in 2015. Shkreli even directed Vyera to continue anticompetitive actions while he was serving a prison sentence on securities fraud charges, Vyera said in court papers filed Wednesday.

Vyera, formerly known as Turing Pharmaceuticals, has between $10 million and $50 million in assets and between $1 million and $10 million in liabilities, according to a Chapter 11 petition filed in Delaware bankruptcy court.

Vyera filed a Chapter 11 plan in court on Wednesday, laying out it its intent to repay creditors through asset sales.

Besides Daraprim, Vyera’s assets include a priority review voucher that could be resold to other companies seeking expedited drug approvals in the U.S. and about $5.6 million in shares of Regnum Corp. Vyera said that recently-sold vouchers have fetched prices between $95 million and $120 million in sales that have occurred since 2020.

Vyera is facing multiple lawsuits related to its Daraprim price hike, including a shareholder action, an antitrust complaint filed by a generic drugmaker, and a demand for legal fees from Duane Morris, the law firm that defended Shkreli in an antitrust action brought by the U.S. Federal Trade Commission. Vyera listed Duane Morris as its largest unsecured creditor in its bankruptcy filing, with a $2.1 million asserted debt.

While Vyera settled the FTC charges related to the Daraprim price hike, Shkreli refused to settle. He was hit with a $64.9 million judgment for anticompetitive conduct, which he has appealed to the 2nd U.S. Circuit Court of Appeals.

A federal court in New York court later appointed a receiver to seize Shkreli shares in Vyera’s parent company and used them to pay the FTC judgment.

Shkreli was convicted in August 2017 of defrauding investors in two hedge funds he ran, and scheming to defraud investors in drugmaker Retrophin (NASDAQ:) Inc, where he had been chief executive.

Read the full article here

News Room May 11, 2023 May 11, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Ukraine and Russia exchange massive air strikes ahead of peace talks

Stay informed with free updatesSimply sign up to the War in Ukraine…

‘Mischief before money’: inside the M&S hackers’ hunt for new targets

The hacking group that pierced the online defences of UK retailer Marks…

Influential economist Stanley Fischer dies

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Early adoption of AI will boost US growth

Business deployment of artificial intelligence has reached a tipping point. UBS is…

US Steel workers see hope of job security in deal with Japan’s Nippon

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

Playa Hotels & Resorts (NASDAQ:PLYA) Delivers Strong Q4 Numbers By Stock Story

By News Room
Stocks

ON24 (NYSE:ONTF) Posts Better-Than-Expected Sales In Q4 By Stock Story

By News Room
Stocks

Evolent Health shares leap on Q4 earnings beat and upbeat guidance By Investing.com

By News Room
Stocks

Chuy’s (NASDAQ:CHUY) Reports Q4 In Line With Expectations But Stock Drops

By News Room
Stocks

Red River Bancshares raises dividend to $0.09 per share

By News Room
Stocks

Ecolab appoints Microsoft executive to board

By News Room
Stocks

Semilux secures $50 million equity deal with White Lion Capital

By News Room
Stocks

US government debt trajectory to push long-term yields higher, says PIMCO

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?